SELLAS Life Sciences Group, Inc. SLS NASDAQ

SELLAS Life Sciences Group, Inc. (SLS) generated $-4.92M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $-4.92M.

Cash conversion ratio was 0.64x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (52/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (?/100) — Cash conversion ratio was 0.64x suggests some earnings are non-cash items

Overall SharesGrow Score: 53/100 with 3/7 criteria passed.